Surg Today (2018) 48:66–72 https://doi.org/10.1007/s00595-017-1555-1 ORIGINAL ARTICLE Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO‑CCTG) 1 2 3 4 5 2 Yasuhiro Miyake · Junichi Nishimura · Takeshi Kato · Masataka Ikeda · Masaki Tsujie · Taishi Hata · 2 2 2 4 1 Ichiro Takemasa · Tsunekazu Mizushima · Hirofumi Yamamoto · Mitsugu Sekimoto · Riichiro Nezu · 2 2 Yuichiro Doki · Masaki Mori · Multi‑ center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO) Received: 21 December 2016 / Accepted: 22 May 2017 / Published online: 20 June 2017 © Springer Japan KK 2017 Abstract or UFT/LV (n = 179) (median age 65 years, colon/ Purpose Oral adjuvant uracil and tegafur plus leucovorin rectum 67.4/32.6%, stage IIB/IIIA/IIIB/IIIC (UFT/LV) is not inferior to standard weekly fluorouracil 11.1/15.7/55.0/18.2%). The 3-year DFS rate was 82.3% and folinate for stage II/III colon cancer. However, protein- in those receiving UFT/LV and 72.1% in those receiv- bound polysaccharide K (PSK) has been evaluated as post- ing UFT/PSK. The non-inferiority of UFT/PSK adjuvant operative adjuvant therapy for colorectal cancer. This report therapy to UFT/LV therapy was not verified ( −9.06%, 90%
Surgery Today – Springer Journals
Published: Jun 20, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud